Antimicrobial activity of polyhexamethylene biguanide nanoparticles against mastitis-causing Staphylococcus aureus

R. F. Leite, J. L. Gonçalves, A. Buanz, C. Febraro, D. Craig, S. Van Winden, L. Good, and M. V. Santos *

Graphical Abstract

Summary
Polyhexamethylene biguanide (PHMB) nanoparticles (NP) developed for this study presented antimicrobial activity against mastitis-causing Staphylococcus aureus at lower concentrations than PHMB alone, chlorhexidine digluconate, povidone-iodine, and sodium dichloroisocyanurate. Thus, PHMB NP present potential for the development of new dipping solutions.

Highlights
- The PHMB NP were developed by layer-by-layer assembly.
- Mastitis-causing Staph. aureus were inhibited by PHMB NP at low concentrations relative to commonly used teat-dip ingredients.
- The NP formulation potentiated the antimicrobial activity of PHMB.
Antimicrobial activity of polyhexamethylene biguanide nanoparticles against mastitis-causing *Staphylococcus aureus*

R. F. Leite,1 J. L. Gonçalves,1 A. Buanz,2 C. Febraro,3 D. Craig,2 S. Van Winden,3 L. Good,3 and M. V. Santos1*

Abstract: Postmilking teat disinfection is one of the main measures used to prevent mastitis caused by contagious pathogens, such as *Staphylococcus aureus*. The present study evaluated the antimicrobial activity of polyhexamethylene biguanide (PHMB) and PHMB nanoparticles (NP) against mastitis-causing *Staph. aureus* using a microdilution assay methodology. A total of 20 mastitis-causing *Staph. aureus* isolates were used to determine the minimum inhibitory concentrations (MIC) of PHMB and PHMB NP compared with 3 disinfectants commonly used for teat disinfection (chlordioxidine digluconate, povidone-iodine, and sodium dichloroisocyanurate). The MIC50 was defined at the concentrations required to inhibit the growth of 90% of *Staph. aureus*. Our results indicated that PHMB NP presented the lowest MIC value (<0.03 µg/mL) to inhibit 90% of *Staph. aureus*, followed by chlordioxidine digluconate (≥0.25 µg/mL) and PHMB (≥0.5 µg/mL). On the other hand, sodium dichloroisocyanurate (≥2500 µg/mL) and povidone-iodine (≥8,000 µg/mL) presented the highest concentrations to inhibit the growth of most *Staph. aureus*. Our preliminary results suggested that both PHMB and PHMB NP have antimicrobial activity against mastitis-causing *Staph. aureus*, which indicates the potential for both to be used as a teat-dip disinfectant to prevent bovine mastitis.

*Staphylococcus aureus* is one of the most common pathogens associated with clinical and subclinical mastitis (Hoekstra et al., 2020). Postmilking teat disinfection is a simple, economical, and effective strategy to avoid IMI caused by *Staph. aureus* (Oliver et al., 1990; Berg et al., 2014). However, some drawbacks related to the use of disinfectants on teat skin for mastitis prevention also need to be considered, such as the possibility of milk iodine concentrations higher than 500 µg/L and the risk of teat skin irritation (Burmester et al., 1998; O’Brien et al., 2013; French et al., 2016). Further, the wide use of a limited range of disinfectants and the increased use of commercial formulations containing low concentrations of the active ingredients may result in bacterial resistance (Maillard, 2013). Monitoring bacterial resistance to disinfectants is essential for monitoring the emergence of resistant pathogens (Davies and Wales, 2019); however, few studies have reported the susceptibility of mastitis-causing pathogens to the disinfectants used for teat disinfection. Polyhexamethylene biguanide (PHMB), a cationic polymer that presents a broad antimicrobial spectrum, can bind to DNA and condense bacterial chromosomes; this mechanism of action may not lead to acquired resistance (Chindera et al., 2016; Sowlati-Hashjin et al., 2020). On the other hand, Müller et al. (2013) reported that PHMB presents a weak interaction with phospholipids from the mammalian cell membrane, and Chindera et al. (2016) reported that once PHMB enters mammalian cells, it is trapped within endosomes and excluded from nuclei. Moreover, previous studies reported the bactericidal and antibiofilm effects of PHMB against virulent *Staph. aureus* (Kamaruzzaman et al., 2016, 2017). Polymer-based nanoparticles (NP) are colloidal particles smaller than 1,000 nm composed by a polymeric nucleus that can be loaded with active compounds (Zielińska et al., 2020). Considering that nanotechnology can increase antimicrobial activity and reduce toxicities (Shimanovich and Gedanken, 2016; Wang et al., 2017), our hypothesis was that PHMB NP would inhibit mastitis-causing *Staph. aureus* at lower concentrations than PHMB. Therefore, this study evaluated the antimicrobial activity of PHMB NP, PHMB, and other disinfectants commonly used for teat disinfection [chlorhexidine digluconate (CHG), povidone-iodine (PVP-I), and sodium dichloroisocyanurate (NaDCC)] against *Staph. aureus* isolated from mastitis using the MIC.

The PHMB NP were developed using layer-by-layer assembly (Firdessa et al., 2015; Martínez-Orellana et al., 2020) in association with chitosan and alginate and were evaluated using dynamic light scattering. For NP synthesis, 5 mL of ultrapure water and 2.5 mL of 1 mg/mL PHMB solution in water (Tecrea) were first combined by magnetic stirring bar (18 mm) was added to the tubes that were mixed by a magnetic stirrer (Cole-Parmer) at 650 rpm for 20 min and left to stand for another 20 min. A 3.75-mL volume of low-molecular-weight chitosan (50,000–190,000 Da; Sigma-Aldrich) in 1% acetic acid was added to make a 1:1.5 weight ratio of PHMB to alginate within 50-mL clear-polypropylene conical centrifuge tubes with self-standing bottoms. A polytetrafluoroethylene stirring bar (18 mm) was added to the tubes that were mixed by a magnetic stirrer (Cole-Parmer) at 650 rpm for 20 min and left to stand for another 20 min. A 3.75-mL volume of low-molecular-weight chitosan (50,000–190,000 Da; Sigma-Aldrich) in 1% acetic acid was added to make a 1:1.5 weight ratio of PHMB to chitosan. The ratio of PHMB alginate to chitosan was defined at the concentrations required to inhibit the growth of 90% of *Staph. aureus*. Then, NP populations were evaluated by dynamic light scattering to measure
particles size, zeta potential polydispersity index, and count rate on a Zetaziser Nano S-90 (Malvern Instruments Ltd.) using DTS1070 cuvettes. The NP presented size <250 nm, polydispersity index <0.5, zeta potential of 60 mV, and count rate of 350 kilocounts/s. Measurements were taken immediately after synthesis and again after 1 wk and 1 mo of storage. No significant changes that could compromise PHMB NP stability, represented by no significant change to their particle size or zeta potential, were observed during storage.

*Staphylococcus aureus* (n = 20) was isolated from mammary quarter milk samples of cows affected by clinical (n = 11; 11 herds) and subclinical (n = 9; 9 herds) mastitis in commercial dairy herds (n = 15) located in Southeast Brazil. These isolates were obtained from previous studies (Leite et al., 2018; Tomazi et al., 2018) and selected due to their resistance (or multiresistance) to antimicrobials commonly used for mastitis treatment (our unpublished data). The *Staph. aureus* isolates were cryopreserved at −80°C in brain heart infusion broth with 20% glycerol. For this study, isolates were retrieved from storage and plated onto blood agar to ensure purity and to confirm their species by MALDI-TOF MS using the direct transfer method (Cameron et al., 2017). Bacterial colonies were analyzed by Microflex LT mass spectrometer (Bruker Daltonics) coupled with Flex Control 3.4 software and MBT Compass 4.1.7 software (Bruker Daltonics). All isolates presented a score of ≥2 for identification as *Staph. aureus*.

The MIC determination of PHMB NP, PHMB, CHG (Riocquimica), PVP-I (Sigma-Aldrich), and NaDCC (Merck and Co.) using the microdilution method described by EUCAST (2019) was adapted and performed in sterile 96-well plates (Gral). Stock solutions of each disinfectant were freshly prepared in sterile ultrapure water at the following concentrations: PHMB and CHG, 20 mg/mL; PVP-I, 64 mg/mL; and NaDCC, 1.4 mg/mL. The PHMB NP were used at the final concentration of 167 µg/mL obtained by laboratory synthesis. For the first column of each plate, we added cation-adjusted Mueller Hinton broth (Becton, Dickinson and Co.) and disinfectants to attain a final volume of 200 µL. In the other columns (2–12), we added 100 µL of Mueller Hinton broth. Serial dilutions were carried out by homogenizing the wells’ contents 5 times and transferring 100 µL from the first column to the second using a manual multichannel pipette. After homogenization of the second column, 100 µL was transferred to the third column, and so on until column 12. Therefore, disinfectants were evaluated at the following range of concentrations: free PHMB and CHG, 0.03 to 64 µg/mL; PVP-I, 7.8 to 16,000 µg/mL; NaDCC, 0.24 to 500 µg/mL; and PHMB NP, 0.03 to 66.8 µg/mL. Two microplates were prepared for each isolate, and wells for negative control of broth sterility and positive control of isolate growth were included for each microplate.

Antimicrobial activity of CHG, PHMB, PVP-I, and NaDCC was evaluated against 20 *Staph. aureus* isolates; for PHMB NP, 10 *Staph. aureus* isolates were selected from 10 dairy herds and selected because they displayed multiresistance or resistance to a high number of antimicrobials used for mastitis treatments by in vitro assays, as mentioned above. The *Staph. aureus* isolates were cultured in brain heart infusion broth (Kasvi) and incubated at 37°C for 24 h. Then, bacterial suspensions were standardized at 0.5 McFarland (1 × 10⁶ cfu/mL) using a nephelometer (Uniscience) in 0.9% sterile saline solution and diluted until a final bacterial count of 5 × 10⁴ cfu/mL; they were then immediately used. A volume of 10 µL of standardized bacterial solution was applied in each well (except for broth sterility controls); the plates were covered and homogenized at 200 rpm for 10 min on a stirring table (Quimis) and then incubated at 37°C. After 18 h, 30 µL of 0.05% thiazoloyl blue tetrazolium bromide (MTT; Sigma-Aldrich) was added to the plates for MIC determination by visual inspection (Leite et al., 2018).

All analyses were performed in duplicate to score the concentrations needed to result in 50% (MIC₅₀) and 90% (MIC₉₀) inhibition. Because disinfectants evaluated in this study belong to different groups of antiseptics in accordance with their chemistry and mode of action, they inhibit pathogen growth at very different concentration ranges (Maillard, 2013). For this reason, disinfectants from the same group were compared considering treatments by 3 major groups: biguanides (PHMB NP, PHMB, and CHG), iodophor (PVP-I), and chlorine (NaDCC). In addition, disinfectants from different groups were compared (all against all). Then, MIC values were evaluated by ANOVA and differences of least squares means using PROC MIXED (SAS version 9.4; SAS Institute Inc.). Differences were considered significant for P-values <0.05.

Disinfectant MIC values were significantly different (P < 0.0001; Table 1). The PHMB NP inhibited *Staph. aureus* growth at the lowest concentration; on the other hand, the highest MIC values were observed for PVP-I, followed by NaDCC. No differences were observed between MIC₅₀ and MIC₉₀ for PHMB NP (<0.03 µg/mL), NaDCC (≥500 µg/mL), and PVP-I (≥8,000 µg/mL). However, for CHG and PHMB, MIC₅₀ values (≥0.25 and ≥0.5 µg/mL, respectively) were one serial concentration higher than MIC₉₀ values (≥0.12 and ≥0.25 µg/mL, respectively). Considering the analysis by disinfectants from the same group, iodophor inhibited 90% of *Staph. aureus* in higher concentrations (≥8,000 µg/mL) than chlorine (P = 0.0138) and biguanides (P < 0.0001), and inhibitory concentrations obtained for biguanides were significantly lower than those obtained for chlorine (P < 0.0001). On the evaluation of biguanides, PHMB NP presented the lowest MIC₉₀ (<0.003 µg/mL) to inhibit *Staph. aureus* isolates compared with PHMB (P < 0.0001) and CHG (P = 0.0036); one serial concentration (P < 0.0001) of PHMB (≥0.5 µg/mL) was higher than the concentration obtained for CHG (≥0.25 µg/mL) to determine the MIC₉₀. Despite the lower number of *Staph. aureus* isolates tested for PHMB NP, only 1 isolate grew at 0.03 µg/mL; the other 9 isolates did not grow in the concentration ranges that were analyzed. In relation to CHG, it was not possible to determine the MIC for 2 isolates because they did not grow at the lowest concentration evaluated (<0.03 µg/mL), and the other isolates (n = 18) were inhibited by 3 consecutive serial concentrations. For PHMB, 4 concentrations inhibited the growth of *Staph. aureus*.

The current study evaluated in vitro antimicrobial activity of PHMB NP against *Staph. aureus* isolates from bovine mastitis. We found that PHMB NP inhibited the growth of 90% of *Staph. aureus* isolates at lower concentrations compared with PHMB, CHG, PVP-I, and NaDCC.

Due to the virulence characteristics of *Staph. aureus*, which often lead to therapy failures, the development of NP technology is considered a potential alternative to overcome the higher microbial resistance of this pathogen (Algharib et al., 2020). In this scenario, some studies have evaluated nano formulations against matitis-
causing *Staph. aureus* for both therapeutic or preventive usage. Orellano et al. (2019) evaluated chitosan NP with a diameter of approximately 138 nm against *Staphylococcus* spp. obtained from mastitis cases. Regarding *Staph. aureus* isolates (n = 3), chitosan NP inhibited their growth at 200 to 400 µg/mL, whereas chitosan concentrations ≥1,600 µg/mL were required to determine the MIC. For CNS (n = 7), inhibitory concentrations of chitosan NP and chitosan varied from 400 to 800 µg/mL and 800 to >1,600 µg/mL, respectively, for most isolates (n = 6). One isolate of *Staph. chromogenes* presented the same MIC value (200 µg/mL) for both compounds. These results described by Orellano et al. (2019) were higher than the MIC values of PHMB NP (<0.03 µg/mL) and free PHMB (≤0.05 µg/mL) against *Staph. aureus* observed in our study.

Chitosan is a biodegradable polymer and is approved as Generally Recognized as Safe by the US Food and Drug Administration (FDA, 2012). Moreover, it has modest antimicrobial activity as well as controlled drug release and mucoadhesive properties (Ali and Ahmed, 2018). For these reasons, it was included in the formulation of the polymer-based NP evaluated in this study. It has been reported that the combination of chitosan and cloxacillin potentiated the antimicrobial activity against 7 CNS isolates from chronic mastitis cases (Breser et al., 2018). Moreover, Ashraf et al. (2012) found that the growth curves of 1 *Eschericia coli* isolate were inhibited by PHMB functionalized silver NP at lower concentrations (0.075–0.15 µg/mL) than PHMB alone (3 µg/mL). Ashraf et al. (2012) suggested that the association of PHMB and silver on an NP formulation potentiated their antimicrobial activity. However, no previous studies evaluated the effects of the association among PHMB, chitosan, and alginate on the potency of antimicrobial activity.

Although the association among chitosan, alginate, and PHMB on the enhancement of antimicrobial activity is unclear, results obtained for PHMB NP highlighted the ability of NP to potentiate antimicrobial activity. Despite belonging to the same antiseptic group, one serial concentration of PHMB (≥0.05 µg/mL) was higher than CHG (≥0.25 µg/mL) to determine MIC<sub>90</sub>. Compared with the results obtained in the present study for CHG (0.25 µg/mL) to inhibit 90% of *Staph. aureus*, Schabauer et al. (2018) found a higher concentration (2 µg/mL) of chlorhexidine diacetate hydrate to determine MIC<sub>90</sub> for 172 *Staph. aureus* from mastitis cases. After chlorhexidine, the lowest concentration was observed for benzalkonium chloride (4 µg/mL). Considering all disinfectants evaluated by Schabauer et al. (2018), gentisaldehyde (1,000 µg/mL) and 2,3-dihydroxybenzaldehyde (833 µg/mL) presented the highest inhibitory concentrations to determine MIC<sub>90</sub>. These values are lower than those found in our study for NaDCC (≥500 µg/mL). However, Schabauer et al. (2018) reported a lower concentration of iodine (MIC<sub>90</sub> = 500 µg/mL) to inhibit evaluated isolates compared with the results obtained by us (MIC<sub>90</sub> = 8,000 µg/mL) and by Azizoglu et al. (2013), who reported an MIC of 1,500 µg/mL to inhibit 29 *Staph. aureus* isolates (78%).

Regarding MIC values, similarities among disinfectants from different classes and differences among disinfectants from the same antiseptic group may be associated with the different methodologies for MIC determination and with the fact that disinfectant formulation varied. In the case of iodine, Azizoglu et al. (2013) evaluated the antimicrobial activity of titratable iodine using the agar dilution technique. On the other hand, microdilution methods were used in our study and in the study by Schabauer et al. (2018). Whereas in our study we evaluated the antimicrobial activity of PVP-I, Schabauer et al. (2018) evaluated a Lugol’s solution containing 5% (wt/wt) iodine and 10% (wt/wt) potassium iodide. Lugol’s solution presents free iodine and rapid lethal effects against pathogens, whereas in PVP-I the iodine forms a complex with the polymer povidone, providing a slow and sustained release of iodine that ensures long-lasting efficacy against pathogens (Eggers, 2019). Moreover, PVP-I present a broad spectrum of antimicrobial activity, and it is safe for in vivo usage. Thus, PVP-I is widely evaluated by ex vivo and in vitro studies despite some difficulties related to the interpretation of results due to the paradoxical higher antimicrobial activity with dilutions until a 0.1% strength solution (Lepelletier et al., 2020); this may also explain the high MIC value (≥8,000 µg/mL) obtained in our study.

In conclusion, we observed that PHMB NP presented the lowest concentrations to inhibit the growth of *Staph. aureus* from bovine mastitis cases by in vitro assay. Despite the high antimicrobial activity against *Staph. aureus* isolates, further analysis of the possible toxicity of PHMB NP against mammary epithelial cells and the evaluation of antimicrobial activity using ex vivo and in vivo assays will help further explain the possible benefits of this approach.

| Table 1. Proportion (%) of mastitis-causing *Staphylococcus aureus* isolates inhibited for each tested concentration of disinfectants and MIC<sub>50</sub> and MIC<sub>90</sub> values<sup>1</sup> |
|-----------------|-----------------|----------------|----------------|----------------|----------------|----------------|----------------|----------------|
| Disinfectant    | MIC (µg/mL)     | MIC<sub>50</sub> | MIC<sub>90</sub> |
| Chlorhexidine digluconate | <0.03 | 0.06 | 0.12 | 0.25 | 0.5 | 1 | 250 | 500 | 4,000 | ≥8,000 | ≥0.12 | ≥0.25 |
| Polyhexamethylene biguanide | 0 | 0 | 10 | 50 | 30 | 10 | 0 | 0 | 0 | 0 | ≥0.25 | ≥0.5 |
| Polyhexamethylene biguanide nanoparticles<sup>4</sup> | 90 | 10 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | <0.03 | <0.03 |
| Povidone-iodine | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 40 | 60 | ≥8,000 | ≥8,000 |
| Sodium dichloroisocyanurate | 0 | 0 | 0 | 0 | 0 | 0 | 40 | 60 | 0 | 0 | ≥500 | ≥500 |

<sup>1</sup>In vitro assays considering isolates (n = 20) of *Staph. aureus*.

<sup>2</sup>MIC required to inhibit growth of 50% of tested isolates.

<sup>3</sup>MIC required to inhibit growth of 90% of tested isolates.

<sup>4</sup>A total of 10 *Staph. aureus* isolates were evaluated.

References

Algharib, S. A., A. Dawood, and S. Xie. 2020. Nanoparticles for treatment of bovine *Staphylococcus aureus* mastitis. Drug Deliv. 27:292–308. https://doi.org/10.1080/10717544.2020.1724209.

Ali, A., and S. Ahmed. 2018. A review on chitosan and its nanocomposites in drug delivery. Int. J. Biol. Macromol. 109:273–286. https://doi.org/10.1016/j.ijbiomac.2017.12.078.
